Search

everythinglearnresearchcommunity

for

Search:↓

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.

Tofacitinib and baricitinib are similarly effective and safe for alopecia areata, but baricitinib works faster.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

Ritlecitinib is a new treatment for severe hair loss in people 12 and older.

Vemurafenib therapy can cause hair loss, but clobetasol propionate foam can help regrow hair.

CS12192 effectively treats alopecia areata with better safety than current options.

Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.

Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.

Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.

Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.

Baricitinib-loaded EVs help hair regrowth in alopecia areata by reducing inflammation and promoting hair follicle regeneration.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.

Tofacitinib helped a woman with total-body hair loss grow her hair back.

Upadacitinib effectively treats skin conditions like eczema and psoriasis and is becoming more widely used and affordable.

Tofacitinib may effectively regrow hair in alopecia totalis patients.

Baricitinib significantly regrows hair in teens with severe alopecia areata.

LGD1069 effectively prevents breast tumors in mice without toxicity.

Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.

Sacituzumab govitecan is effective but has side effects like hair loss and diarrhea in treating metastatic triple-negative breast cancer.

Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.

Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

Ruxolitinib cream may help treat severe hair loss in children.

Existing drugs, including a blood pressure medication, show promise as new treatments for influenza.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.